CELUHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 12 Sept 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Celularity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (9): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CELU, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 14 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2025 | WBB Securities | Upgrade | Buy | — |
| 9 Sept 2025 | WBB Securities | Upgrade | Buy | $6.00 |
| 18 Aug 2025 | WBB Securities | Initiates | Speculative Buy | — |
| 30 Jan 2023 | HC Wainwright & Co. | Maintains | Buy | $15 → $2.50 |
| 30 Jan 2023 | Morgan Stanley | Downgrade | Underweight | $5.00 → $1.00 |
| 22 Dec 2022 | Oppenheimer | Downgrade | Perform | — |
| 12 Sept 2022 | Morgan Stanley | Maintains | Equal-Weight | $8.00 → $5.00 |
| 25 Aug 2022 | Alliance Global Partners | Initiates | Buy | $15 |
| 23 Aug 2022 | Truist Securities | Maintains | Hold | $10 → $6.00 |
| 22 June 2022 | HC Wainwright & Co. | Initiates | Buy | — |
| 6 Apr 2022 | Truist Securities | Downgrade | Hold | — |
| 28 Jan 2022 | Oppenheimer | Initiates | Outperform | — |
| 24 Nov 2021 | Morgan Stanley | Initiates | Equal-Weight | — |
| 19 Oct 2021 | Truist Securities | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CELU appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Celularity, Inc. returned −39.5% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 69% of US stocks
Cheaper than 59% of US stocks
Cheaper than 72% of US stocks
Higher than 3% of US stocks
Higher than 5% of US stocks
Higher than 2% of US stocks
Higher than 8% of US stocks
Higher than 85% of US stocks
Higher than 99% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Celularity, Inc. has a market value of $40.8M and an enterprise value of $110.4M.
Revenue in the twelve months to 31 Dec 2025: $26.6M. The latest quarter shrank 77.4% year on year.
Net income over the same four quarters: −$91.7M, a −345.4% net margin.
Free cash flow in the twelve months to 31 Dec 2025: −$13.3M, after $0.0 of capital spending.
Trailing P/E: 2.3×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Celularity, Inc. employs 115 people — $231K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Celularity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Celularity Inc. and MuseCell Innovations announced a U.S. manufacturing collaboration to produce Dezawa MuseCells at Celularity's facility in Florham Park, New Jersey.
Why it matters — This partnership expands Celularity's manufacturing role in the Dezawa MuseCell platform, potentially broadening its commercial and production footprint.
Celularity announced that on August 21, 2026, it received a notification from Nasdaq stating the company is not in compliance with Listing Rule 5250(c)(1) because it has not filed its quarterly report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Form 10-Q for the period ended March 31, 2026.
Why it matters — Delinquent filing of required periodic financial reports puts Celularity's Nasdaq listing compliance at risk, which is a significant concern for shareholders monitoring the company's regulatory standing.
As at 12 Sept 2026, Celularity, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).
No analyst covering Celularity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CELU are extrapolating price history, which says nothing about the business.
Celularity, Inc. returned -39.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Celularity Inc. Class A Common Stock represents the equity of Celularity Inc., a cellular and regenerative medicine company focused on developing placental-derived therapies and biomaterial products.
The most recent item we track (Business Wire, 27 Aug 2026): "Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform". Celularity Inc. and MuseCell Innovations announced a U.S. manufacturing collaboration to produce Dezawa MuseCells at Celularity's facility in Florham Park, New Jersey.
Celularity Inc. Class A Common Stock represents the equity of Celularity Inc., a cellular and regenerative medicine company focused on developing placental-derived therapies and biomaterial products. Celularity’s current business centers on three operating segments: Cell Therapy, Degenerative Disease, and BioBanking. The Cell Therapy segment develops off-the-shelf, cryopreserved allogeneic cell therapies, including programs based on mesenchymal-like adherent stromal cells, natural killer cells, and engineered T-cells for oncology, immune, infectious, and age-related diseases. The Degenerative Disease segment supports products used in surgical and wound care markets, while BioBanking provides storage services for stem cells from umbilical cords and placentas. Headquartered in Florham Park, New Jersey, Celularity occupies a niche within biotechnology that combines regenerative medicine research with commercial biobanking and biomaterials services.
CEO Dr. Robert Joseph Hariri M.D., Ph.D. · 115 employees · United States · https://www.celularity.com
